N

Nanjing Vazyme Biotech Co Ltd
SSE:688105

Watchlist Manager
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Watchlist
Price: 22.57 CNY -0.4% Market Closed
Market Cap: 9B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Nanjing Vazyme Biotech Co Ltd

Wall Street analysts forecast Nanjing Vazyme Biotech Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Nanjing Vazyme Biotech Co Ltd is 25.14 CNY with a low forecast of 22.51 CNY and a high forecast of 28.35 CNY.

Lowest Forecast
Wall Street Target
22.51 CNY
0% Downside
Average Forecast
Wall Street Target
25.14 CNY
11% Upside
Highest Forecast
Wall Street Target
28.35 CNY
26% Upside
Lowest
Price Target
22.51 CNY
0% Downside
Average
Price Target
25.14 CNY
11% Upside
Highest
Price Target
28.35 CNY
26% Upside
Nanjing Vazyme Biotech Co Ltd Competitors:
Price Targets
ELDN
Eledon Pharmaceuticals Inc
227% Upside
VICO
Vicore Pharma Holding AB
320% Upside
CMRX
Chimerix Inc
2% Upside
M
MAAT
Maat Pharma SA
213% Upside
ELDN
Eledon Pharmaceuticals Inc
227% Upside
VICO
Vicore Pharma Holding AB
320% Upside
CMRX
Chimerix Inc
2% Upside
M
MAAT
Maat Pharma SA
213% Upside
HALO
Halozyme Therapeutics Inc
17% Upside
TWST
Twist Bioscience Corp
37% Upside
N
4893
Noile-Immune Biotech Inc
210% Upside
ANIK
Anika Therapeutics Inc
63% Upside

Revenue
Forecast

Revenue Estimate
Nanjing Vazyme Biotech Co Ltd

For the last 5 years the compound annual growth rate for Nanjing Vazyme Biotech Co Ltd's revenue is 39%. The projected CAGR for the next 3 years is 19%.

39%
Past Growth
19%
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Nanjing Vazyme Biotech Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Nanjing Vazyme Biotech Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Nanjing Vazyme Biotech Co Ltd's stock price target?
Price Target
25.14 CNY

According to Wall Street analysts, the average 1-year price target for Nanjing Vazyme Biotech Co Ltd is 25.14 CNY with a low forecast of 22.51 CNY and a high forecast of 28.35 CNY.

What is Nanjing Vazyme Biotech Co Ltd's Revenue forecast?
Projected CAGR
19%

For the last 5 years the compound annual growth rate for Nanjing Vazyme Biotech Co Ltd's revenue is 39%. The projected CAGR for the next 3 years is 19%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.